Article ID,Publication Year,Reference,US$/QALY *,Ratio Description,PubMed ID,Target Population,Intervention Description,Title,Comparator Description,Impact
2017-01-23877,2017,Bardach 2017 BMC Public Health,130000,"Human Papillomavirus (HPV): bivalent vaccine against HPV 16 and 18 VERSUS Human Papillomavirus (HPV): bivalent vaccine against HPV 16 and 18 (HPV): quadrivalent vaccine against HPV 6, 11, 16, and 18 IN Specific disease- Human Papillomavirus (HPV); Age-; Gender- Female; Country- Venezuela.",28148228,Specific disease- Human Papillomavirus (HPV); Age-; Gender- Female; Country- Venezuela.,Human Papillomavirus (HPV): bivalent vaccine against HPV 16 and 18,Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.,"Human Papillomavirus (HPV): bivalent vaccine against HPV 16 and 18 (HPV): quadrivalent vaccine against HPV 6, 11, 16, and 18",NE
2017-01-23877,2017,Bardach 2017 BMC Public Health,Cost-Saving,Human Papillomavirus (HPV): bivalent vaccine against HPV 16 and 18 VERSUS None IN Specific disease- Human Papillomavirus (HPV); Age-; Gender- Female; Country- Venezuela.,28148228,Specific disease- Human Papillomavirus (HPV); Age-; Gender- Female; Country- Venezuela.,Human Papillomavirus (HPV): bivalent vaccine against HPV 16 and 18,Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.,None,SE
2017-01-23877,2017,Bardach 2017 BMC Public Health,Cost-Saving,"Human Papillomavirus (HPV): quadrivalent vaccine against HPV 6, 11, 16, and 18 VERSUS None IN Specific disease- Human Papillomavirus (HPV); Age-; Gender- Female; Country- Venezuela.",28148228,Specific disease- Human Papillomavirus (HPV); Age-; Gender- Female; Country- Venezuela.,"Human Papillomavirus (HPV): quadrivalent vaccine against HPV 6, 11, 16, and 18",Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.,None,SE
1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
